TARGETING MUTANT P53 FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER: A PRE-CLINICAL STUDY

被引：0
|
作者：
Lawless, A. [1 ]
O'Grady, S. [2 ]
Tang, M. [2 ]
Duffy, M. J. [2 ,3 ]
机构：
[1] Univ Coll Dublin, UCD Sch Med, Dublin 4, Ireland
[2] Univ Coll Dublin, Conway Inst Biomed & Biomol Res, Dublin 4, Ireland
[3] St Vincents Univ Hosp, UCD Clin Res Ctr, Dublin, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2022年 / 191卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] The benefits of Didox in triple negative breast cancer treatment targeting mutant p53
    Sultana, Nahid
    Wilson, Elizabeth A.
    Shah, Khyati N.
    Elford, Howard L.
    Faridi, Jesika S.
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer
    Rajaram, Subhasree
    Synnott, Naoise C.
    Crown, John
    Madden, Stephen F.
    Duffy, Michael J.
    TRANSLATIONAL ONCOLOGY, 2024, 46
  • [3] Targeting triple negative breast cancer: Is p53 the answer?
    Turner, Natalie
    Moretti, Erica
    Siclari, Olimpia
    Migliaccio, Ilenia
    Santarpia, Libero
    D'Incalci, Maurizio
    Piccolo, Stefano
    Veronesi, Andrea
    Zambelli, Alberto
    Del Sal, Gianni
    Di Leo, Angelo
    CANCER TREATMENT REVIEWS, 2013, 39 (05) : 541 - 550
  • [4] Mutant p53 as a Therapeutic Target for the Treatment of Triple-Negative Breast Cancer
    Synnott, N.
    Crown, J.
    Duffy, M. J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E41 - E41
  • [5] Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?
    Synnott, Naoise C.
    Pierce, Aisling
    Mullooly, Maeve
    Caiazza, Francesco
    McGowan, Patricia M.
    O'Donovan, Norma
    Crown, John
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] The mutant p53 mouse as a pre-clinical model
    Jackson, J. G.
    Lozano, G.
    ONCOGENE, 2013, 32 (37) : 4325 - 4330
  • [7] The mutant p53 mouse as a pre-clinical model
    J G Jackson
    G Lozano
    Oncogene, 2013, 32 : 4325 - 4330
  • [8] Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott, N. C.
    Murray, A.
    McGowan, P. M.
    Kiely, M.
    Kiely, P. A.
    O'Donovan, N.
    O'Connor, D. P.
    Gallagher, W. M.
    Crown, J.
    Duffy, M. J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 234 - 246
  • [9] Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?
    Synnott, Naoise C.
    Bauer, Matthias R.
    Madden, Stephen F.
    Murray, Alyson M.
    Klinger, Rut
    O'Donovan, Norma
    O'Connor, Darran
    Gallagher, William M.
    Crown, John
    Fersht, Alan R.
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Pre-clinical studies of a mutant p53 reactivating drug in pancreatic cancer
    Yu, Xin
    Tsang, Ashley T.
    Li, Zhe
    Eng, Oliver S.
    Lin, Hongxia
    Gounder, Murugesan
    Carpizo, Darren R.
    CANCER RESEARCH, 2015, 75
12345